38 studies found for:    PSMA
Show Display Options
Rank Status Study
1 Completed Efficacy of Portion Size Measurement Aids
Conditions: Nutrition Assessment;   Obesity
Intervention: Behavioral: Portion Size Measurement Aids (PSMAs)
2 Recruiting BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)
Conditions: GBM;   Glioblastoma Multiforme;   Gliosarcoma
Intervention: Drug: PSMA ADC
3 Enrolling by invitation An Open-label Treatment Extension of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Condition: Prostate Cancer
Intervention: Drug: PSMA ADC
4 Completed Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: PSMA ADC
5 Recruiting A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Condition: Prostate Cancer
Intervention: Drug: PSMA ADC
6 Active, not recruiting
Has Results
PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment
Condition: Prostate Cancer
Interventions: Biological: Peptide Vaccine;   Drug: Poly IC-LC
7 Recruiting Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)
Condition: Prostate Cancer
Interventions: Biological: engineered autologous T cells;   Drug: cyclophosphamide
8 Completed Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: PSMA ADC
9 Completed Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel
Condition: Prostate Cancer
Intervention: Biological: rsPSMA protein plus Alhydrogel® vaccine
10 Recruiting Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
Condition: Monitor Adverse Events
Intervention: Drug: Anti-PSMA Designer T Cells
11 Active, not recruiting Vaccine Therapy in Treating Patients With Kidney Cancer
Condition: Kidney Cancer
Interventions: Biological: human prostate-specific membrane antigen plasmid DNA vaccine;   Biological: mouse prostate-specific membrane antigen plasmid DNA vaccine
12 Recruiting Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: 18F-DCFBC
13 Recruiting Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
Condition: Prostate Cancer
Intervention: Biological: Gene Modified T Cells
14 Not yet recruiting Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Biological: anti-PSMA monoclonal antibody MDX1201-A488;   Procedure: robot-assisted laparoscopic surgery;   Other: diffuse optical imaging;   Other: pharmacological study
15 Active, not recruiting Evaluation of a Transrectal Scintigraphic Detector(ProxiScanTM) for Detection of Primary Prostate Cancer
Condition: Suspected Primary Prostate Cancer
Intervention: Device: ProxiScan (scintigraphic rectal probe)
16 Active, not recruiting Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: 18F-DCFBC
17 Recruiting Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer
Condition: Metastatic Prostate Cancer
Intervention: Drug: 18F-DCFBC
18 Completed Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Condition: Prostate Cancer
Interventions: Biological: PSA prostate cancer vaccine;   Biological: recombinant interleukin-12
19 Completed Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
Conditions: Ovarian;   Melanoma;   Renal;   Prostate;   Colorectal;   Endometrial Carcinoma;   Cervical Carcinoma;   Testicular Cancer;   Thyroid Cancer;   Small Cell Lung Carcinoma;   Mesothelioma;   Breast Carcinoma;   Esophageal Carcinoma;   Gastric Cancer;   Pancreatic Carcinoma;   Neuroendocrine Cancer;   Liver Cancer;   Gallbladder Cancer;   Biliary Tract Cancer;   Anal Carcinoma;   Bone Sarcomas;   Soft Tissue Sarcomas;   Carcinoma of Unknown Origin, Primary
Intervention: Biological: PSMA/PRAME
20 Not yet recruiting Imaging of Residual Tumor During Prostatectomy
Conditions: Prostate Cancer;   Prostatectomy
Intervention:

Previous Page Studies Shown (1-20) Next Page (21-38) Show next page of results
Indicates status has not been verified in more than two years